Liquidia Corp (LQDA)

$LQDA but they still cannot sell the product right? Is there a timeline for the patent cancellation case?

$LQDA Not my words. Not my opinion. 24% droupout rate.

$LQDA this is gonna be so fun to short!

$LQDA flying 🚀

$LQDA buy these now.

$LQDA That's a lot of cash burn.

$LQDA Just a little update. Nothing Special...

$LQDA see yall at $80/share. 🔮

$LQDA Someone bought 10k Oct 25c's. Almost 2m worth. I think they have some confidence in earnings.

$LQDA Plenty of options bets here. ER date not confirmed yet.

$LQDA negative earnings trend alert!

$LQDA Sell before the news!! #HighDiscontinuationRate #MountingLegalExpenses #CashBurn #InevitableDillution

$LQDA "Heads up alert! Upcoming earnings on Friday, 8/8/2025 for $LQDA Consensus Signal: Bullish (7.2) ### Liquidia Corporation (NASDAQ: LQDA) Analysis Liquidia Corporation has been gaining traction in the market, as evidenced by its recent performance and strategic developments. The company's stock saw a rally of 12% over the past week despite growing losses, which suggests investor confidence in its future prospects. This optimism is likely driven by Liquidia's successful securing of a $50 million injection from Healthcare Royalty (HCRx), which will accelerate the commercial launch of Yutrepia. The favorable court ruling against United Therapeutics Corp.'s request for a preliminary injunction further strengthens Liquidia's position in the market. From a financial perspective, Liquidia's P/E ratio and EPS growth are not directly available, but the company's revenue forecasts are expected to improve with the commercial success of Yutrepia. Comparatively, Liquidia is positioned well among its biopharmaceutical peers, particularly as a low-priced pharma stock with a potential for high returns. The market's reaction to Liquidia's recent developments and the upgrade in its Relative Strength Rating indicates a positive outlook. ### Upcoming Earnings and Performance Expectations As Liquidia moves forward, the upcoming earnings reports will be crucial in determining the stock's trajectory. Historically, the company has faced challenges with losses, but the recent financial backing and legal victories suggest a potential turnaround. Analyst consensus estimates are likely to focus on revenue growth driven by Yutrepia's performance in the market. The anticipated impact of these earnings on the stock could be significant, especially if Liquidia meets or exceeds market expectations, thereby reinforcing investor confidence. ### Sector Performance Liquidia operates within the biopharmaceutical sector, which has shown mixed results. While some companies have struggled, others have experienced robust growth, driven by innovation and strategic investments. The sector overall has been influenced by broader market trends, including economic data and corporate earnings. Notably, growth companies within this sector, especially those with substantial insider ownership, have been appealing to investors due to potential alignment of interests and enhanced performance prospects. Liquidia's recent strategic moves position it well within this dynamic landscape, with potential for significant growth in the coming periods. - Funds were net buyers of $LQDA during the previous reporting quarter. - Funds with large holdings in $LQDA include: - Deerfield Management Co, MV: $24MM. New position. Fund Rank: 90% www.deerfield.com - Adage Capital P, MV: $7MM. Fund Rank: 86% www.adagecapital.com - Acuta Capital Partners LLC, MV: $2MM. Fund Rank: 56% acutacapital.com - Last 10 days performance: 13% - Last 30 days performance: 55% - Last 90 days performance: 18% Some of the latest news articles: - Title: Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates Publication Date: 7/31/2025 1:15:03 PM, Source: yahoo URL: https://finance.yahoo.com/news/vericel-corporation-vcel-reports-q2-131503795.html?.tsrc=rss - Title: Liquidia's Yutrepia Drug Launch Expectations 'Overly Optimistic,' Oppenheimer Says Publication Date: 7/29/2025 3:17:36 PM, Source: yahoo URL: https://finance.yahoo.com/news/liquidia-apos-yutrepia-drug-launch-151736641.html?.tsrc=rss - Title: Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? Publication Date: 7/24/2025 12:00:47 PM, Source: yahoo URL: https://finance.yahoo.com/m/8ca502bb-5430-3721-bd5c-1b3ce0fa4b4b/insmed-is-trading-at-a.html?.tsrc=rss - Title: 3 Growth Companies With Insider Ownership Up To 25% Publication Date: 7/18/2025 5:35:30 PM, Source: yahoo URL: https://finance.yahoo.com/news/3-growth-companies-insider-ownership-173530037.html?.tsrc=rss Follow us on stocktwits.com and Substack (chessgmstocks.substack.com). Not a financial advice. Not a trading signal."

$LQDA whomever is playing the game, (hint, it’s not retail) I hope you get your balls in a vice. 100% bullsh!t but ok, only flippers will freak out anyway. Solid news all around and simply easy for you to manipulate, like your mom. Your puts will bury you.

$LQDA Hope we get the news weve all waited years for next week!

$LQDA just reverted 4% higher to -4% (~2Mv) moments ago, 08/15 options, follow for more volatility.

$LQDA what happened 2pm to drive this drop?

$LQDA wtaf is wrong with this stock

$LQDA very bad day even technically. Let’s hope it might recover like yesterday to 18.50/18.70 area and the 2 supports in area 17 can resist otherwise it’s hard to break 20 in case of positive q2 first month sales and good sales metrics for q3 given by July sales

Investing in $LQDA is like playing the board game, "Chutes & Ladders". Time to slide back down a chute. New patients trying Yutripia are dropping off at record #s. Just like in the trial. Not very ... INSPIRE-ing. 🤮🐻

$LQDA strong end of Lqda from minimum of the day 18.33 to 18.69 in less than 1 hour and with 40% of daily volumes. Its a good sign and sell off could be ended and its technically healthy cause it was in oversold area

$LQDA pump pump-a-dump! No